ChemRxiv
These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. For more information, please see our FAQs.
1/1
2 files

Screening Antibodies Raised Against the Spike Glycoprotein of SARS-CoV-2 to Support the Development of Rapid Antigen Assays

preprint
submitted on 01.09.2020, 15:38 and posted on 02.09.2020, 07:34 by Jason Cantera, David Cate, Allison Golden, Roger Peck, Lorraine Lillis, Gonzalo Domingo, Eileen Murphy, Bryan Barnhart, Caitlin E Anderson, Luis F Alonzo, Veronika Glukhova, Gleda Hermansky, Brianda Barrios-Lopez, Ethan Spencer, Samantha Kuhn, Zeba Islam, Benjamin Grant, Lucas Kraft, Karine Herve, Valentine de Puyraimond, Yuri Hwang, Puneet K Dewan, Bernhard H Weigl, Kevin P Nichols, David Boyle

The spike glycoprotein of SARS-CoV-2 is a highly conserved surface protein and as such may represent a good target for immunoassay detection. We screened a variety of antibodies that were reactive to the S glycoprotein in a highly sensitive liquid immunoassay format and also on paper-based or lateral flow assay (LFA) to assess their analytical performance. Our findings included significant variation in performance when using different sources of S antigen. We identified several antibody pairs that had an LOD of below 10 pg/mL in the liquid immunoassay format with the lowest being 3 pg/mL. The antibodies were highly specific to SARS-Cov-2 based on cross reactivity screening with other human CoVs. The LFA screening found some different optimal antibody pairs from the pool of candidate antibodies used but a several antibodies were observed to have high performance with either immunoassay format.


Funding

INV-016821 BMGF

D18AC0000 DARPA

History

Email Address of Submitting Author

dboyle@path.org

Institution

PATH

Country

United States

ORCID For Submitting Author

0000-0003-4019-9037

Declaration of Conflict of Interest

BB, LK, KH, VP and YH are employees of AbCellera Biologics. All other authors have no competing interests.

Version Notes

Version 1.

Exports